Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

Recent Ebola virus disease epidemics have highlighted the need for effective vaccines and
therapeutics to prevent future outbreaks. Antibodies are clearly critical for control of this …

Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …

Summary Filoviruses, including Ebola and Marburg, cause fatal hemorrhagic fever in
humans and primates. Understanding how these viruses enter host cells could help to …

Ebola virus causes hemorrhagic fever with a high case fatality rate for which there is no
approved therapy. Two human monoclonal antibodies, mAb100 and mAb114, in …

Antibodies have been used to prevent or treat viral infections since the nineteenth century,
but the full potential to use passive immunization for infectious diseases has yet to be …

The pandemic COVID-19 has spread widely throughout the globe and has been responsible
for millions of deaths worldwide. Recently, it has been identified that there is no specific and …

Recent studies have suggested that antibody-mediated protection against the Ebolaviruses
may be achievable, but little is known about whether or not antibodies can confer cross …

Bio-layer interferometry (BLI) real-time, label-free technology has greatly contributed to
advances in vaccine research and development. BLI Octet platforms offer high-throughput …

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of
lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral …